GZD824 Inhibits GCN2 and Sensitizes Cancer Cells to Amino Acid Starvation Stress

Yu Kato, Kazuhiro Kunimasa, Mizuki Takahashi, Ayaka Harada, Ikuko Nagasawa, Masanori Osawa, Yoshikazu Sugimoto, and Akihiro Tomida

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (Y.K., K.K., M.T., I.N., A.T.); and Divisions of Chemotherapy (Y.K., M.T., Y.S.) and Physics for Life Functions (A.H., M.O.), Faculty of Pharmacy, Keio University, Minato-ku, Tokyo, Japan

Received May 14, 2020; accepted September 24, 2020

ABSTRACT

Eukaryotic initiation factor 2α (eIF2α) kinase general control nonderepressible 2 (GCN2) drives cellular adaptation to amino acid limitation by activating the integrated stress response that induces activating transcription factor 4 (ATF4). Here, we found that a multikinase inhibitor, GZD824, which we identified using a cell-based assay with ATF4 immunostaining, inhibited the GCN2 pathway in cancer cells. Indeed, GZD824 suppressed GCN2 activation, eIF2α phosphorylation, and ATF4 induction during amino acid starvation stress. However, at lower nonsuppressive concentrations, GZD824 paradoxically stimulated eIF2α phosphorylation and ATF4 expression in a GCN2-dependent manner under unstressed conditions. Such dual properties conceivably arose from a direct effect on GCN2, as also observed in a cell-free GCN2 kinase assay and shared by a selective GCN2 inhibitor. Consistent with the GCN2 pathway inhibition, GZD824 sensitized certain cancer cells to amino acid starvation stress similarly to ATF4 knockdown. These results establish GZD824 as a multikinase GCN2 inhibitor and may enhance its utility as a drug under development.

SIGNIFICANCE STATEMENT

GZD824, as a direct general control nonderepressible 2 (GCN2) inhibitor, suppresses activation of the integrated stress response during amino acid limitation, whereas it paradoxically stimulates this stress-signaling pathway at lower nonsuppressive concentrations. The pharmacological activity we identify herein will provide the basis for the use of GZD824 to elucidate the regulatory mechanisms of GCN2 and to evaluate the potential of the GCN2–activating transcription factor 4 pathway as a target for cancer therapy.
in cancer cells that express asparagine synthetase at low levels (Nakamura et al., 2018).

It has been suggested that the GCN2-mediated ISR pathway provides promising targets for cancer therapy, but there are few GCN2 inhibitors available. In this study using a kinase inhibitor library, we screened compounds that inhibit the GCN2 pathway. As a result, we successfully identified GZD824, which is a known BCR-ABL inhibitor (Ren et al., 2013) that prevents GCN2 pathway activation during amino acid starvation stress. We further found that GZD824 directly inhibited GCN2 kinase activity and sensitized certain cancer cell lines to amino acid starvation stress. Our findings from this exploratory study indicate that GZD824 is useful to investigate the role of GCN2 in cellular stress adaptation as a target for cancer therapy.

Materials and Methods

Cell Culture and Regents. Human fibrosarcoma cell line HT1080 and non–small cell lung cancer cell lines NCI-H460 and A549 were obtained from the American Type Culture Collection (Manassas, VA). HT1080, NCI-H460, and A549 cells were maintained in RPMI-1640 (Wako Pure Chemical Industry, Osaka, Japan) with 10% fetal bovine serum (Merk, Burlington, MA) as described previously (Saito et al., 2009). All the cells were checked to be mycoplasma-free. GZD824 (Selleck Chemicals, Houston, TX), GCN2iB (MedChemExpress, Monmouth Junction, NJ), OSI2656157 (Merk), halofuginone (Merk), tunicamycin (Nacalai Tesque, Kyoto, Japan), and thapsigargin (Wako) were dissolved in DMSO as stock solutions previously (Saito et al., 2009). All the cells were checked to be mycoplasma-free. GZD824 (Selleck Chemicals, Houston, TX), GCN2iB (MedChemExpress, Monmouth Junction, NJ), OSI2656157 (Merk), halofuginone (Merk), tunicamycin (Nacalai Tesque, Kyoto, Japan), and thapsigargin (Wako) were dissolved in DMSO as stock solutions (final concentration was less than 0.5% solvent). Histidinol (Merk) was dissolved in sterilized distilled water.

RNA Interference. Silencing of human GCN2, PERK, and ATF4 expression was performed using ON-TARGETplus SMARTpool siRNAs (GCN2: L-005314, PERK: L-004833-00, ATF4: L-005125; GE Healthcare, Little Chalfont, UK) or Silencer Select siRNA (ATF4: s1702; Thermofisher Scientific, Waltham, MA) with Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific). ON-TARGETplus SMARTPool and Silencer Select siRNAs were used at 20 and 5 nM, respectively. Cells were transfected with each siRNA according to the manufacturers’ reverse-transfection protocol.

Immunofluorescence Staining. Cells were seeded in a 96-well black plate. The cells were treated with reagents at the indicated concentration and time. The cells were fixed in 4% paraformaldehyde for 15 minutes and then permeabilized with 0.3% Triton X-100 in 4% BSA-PBS for 1 hour. The cells were incubated with an anti-ATF4 antibody (11815; Cell Signaling Technology, Beverly, MA) in 1% BSA-PBS overnight at 4°C. Then the primary antibody was reacted with an anti-rabbit IgG secondary antibody conjugated with Alexa Fluor-488 (Thermo Fisher Scientific) in 1% BSA-PBS for 1 hour. The nucleus was counterstained with Hoechst 33342 (Thermo Fisher Scientific). Fluorescence images were obtained by an IN CELL ANALYZER 6000 (GE Healthcare). Quantification of the nuclear ATF4 intensity was performed using IN CELL Developer Toolbox software (GE Healthcare).

Immunoblot Analysis. Immunoblot analysis was performed as described previously (Saito et al., 2009). Briefly, cell lysates were prepared using SDS lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 50 mM dithiothreitol, and 10% glycerol). Protein concentrations were determined using a Bio-Rad protein assay (Bio-Rad, Hercules, CA). Protein samples were subjected to SDS-PAGE and subsequently transferred onto a nitrocellulose membrane. Membranes were incubated with primary antibodies against phosphorylated (phospho)-GCN2 (Thr989) (ab75836), PERK (ab65142), and eIF2α (ab5369) (Abcam, Cambridge, UK) as well as GCN2 (3302), phospho-eIF2α (Ser51) (3398), ATF4 (11815), and Ribosomal Protein S3 (RPS3) (9538) (Cell Signaling Technology). After washing, the membranes were further incubated with appropriate secondary antibodies (Anti-Mouse IgG, HRP-Linked Whole Ab Sheep or Anti-Rabbit IgG, HRP-Linked Whole Ab Donkey (GE Healthcare)). The specific signals were detected using Western Lightening plus ECL (Perkin Elmer, Waltham, MA).

In Vitro Kinase Assay. Eight micromolar of recombinant GCN2 protein (active; final concentration: 30 nM; SignalChem, Richmond, Canada) in reaction buffer (20 mM Hepes, pH 7.4, 5 mM MgCl₂, and 1 mM dithiothreitol) was preincubated with 0.2 μM of GZD824, dasatinib, or GCN2iB for 60 minutes at 30°C. Then GCN2 was incubated with 12 μl of 2 mM ATP (Sigma) and recombinant eIF2α (final concentration: 160 nM; SignalChem) for 3 hours at 30°C. These samples were mixed with SDS lysis buffer (250 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 0.16% bromophenol blue, and 20% 2-mercaptoethanol) and boiled at 100°C for 15 minutes. The samples were then subjected to immunoblot analysis as described in 2.4. The immunoblots were quantified using ImageJ (http://rsweb.nih.gov/ij/) under the Gel Analysis Tool.

Structural Comparison and Preparation of a Docking Model of the GCN2-GZD824 Complex. A docking model of the GCN2-GZD824 complex was prepared using coordinates of the GCN2-KAV (Protein Data Bank identification: 6N3L) and ABL-AP24534 (Protein Data Bank identification: 3OXZ) complexes. First, subunit A of the GCN2-KAV complex was superposed on subunit A of the ABL-AP24534 complex with the secondary-structure matching—Superpose routine of Coot (Emsley and Cowtan, 2004; Krissinel and Henrick, 2004), resulting in the root-mean-square deviation of 1.81 Å. We confirmed that KAV and AP24534 in the complex structure were superposed well and then replaced the coordinates of KAV in the GCN2-KAV complex with those of the superposed AP24534. Second, we replaced the imidazo[1,2-b]pyridazin group of AP23534 to the 1H-pyrazolo[3,4-b]pyridine group to obtain GZD824. All molecular graphics in this study were prepared using MacPyMOL version 2.0 (Schrodinger, LLC).

Cell Viability Assay. Cells were seeded in a 96-well plate and treated with the indicated concentrations of agents. After 48 hours, cell viability was measured by the Cell Titer-Glo luminescent cell viability assay (Promega, Madison, WI). Cell viability is shown as the percentage of the control.

Detection of Apoptotic Cells. Cells were seeded in a 96-well plate and treated with the indicated concentrations of agents. After 48 hours, nuclei were stained with 10 μg/ml Hoechst 33342 (Thermo Fisher Scientific) for 10 minutes. Fluorescence images were acquired with the IN CELL ANALYZER 6000. Apoptotic cells were determined by nuclear condensation and fragmentation. The percentage of apoptotic cells was calculated by dividing the number of apoptotic cells by the total number of cells.

Statistical Analysis. Quantitative results are presented as mean ± S.D. (n ≥ 3). A two-tailed Student’s t test was used to evaluate the significance of differences between two groups. A value of P < 0.05 was considered statistically significant.

Results

Identification of GZD824 as a GCN2-ATF4 Pathway Inhibitor. To evaluate activation of the ISR promptly and quantitatively, we examined expression levels of ATF4 in nuclei by immunofluorescence staining of HT1080 cells (Fig. 1A). Treatments of cells with halofuginone (prolyl transfer RNA synthetase inhibitor) (D’Aniello et al., 2015) and tunicamycin (N-glycosylation inhibitor) (Gahnberg et al., 1980) for 6 hours induced nuclear ATF4, which was prevented by siRNAs against GCN2 and PERK, respectively. Thus, we found that halofuginone activated the GCN2 arm of the ISR, whereas tunicamycin activated the PERK arm. Using this system, we screened a kinase inhibitor library (355 compounds at 2 μM each) and identified GZD824 (Supplemental Fig. 1), a known
BCR-ABL inhibitor, which preferentially prevents activation of the GCN2 arm compared with the PERK arm. Indeed, 2 μM GZD824 prevented ATF4 induction during halofuginone stress but only marginally during tunicamycin stress in HT1080 cells (Fig. 1, B and C). Conversely, GSK2656157, a specific inhibitor of PERK (Atkins et al., 2013), suppressed ATF4 induction under stress conditions caused by tunicamycin but not halofuginone (Fig. 1C). Immunoblot analysis consistently revealed that GZD824 prevented ATF4 induction under GCN2-activating conditions due to halofuginone addition for 6 hours and glutamine withdrawal for 18 hours but not under PERK-activating conditions due to tunicamycin addition for 6 hours and glucose withdrawal for 18 hours (Fig. 1, D and E). In addition, phosphorylation of GCN2 at T899, a marker of activation, was suppressed by GZD824, but it did not affect the phosphorylation status of PERK, as detected by an upward mobility shift. These results demonstrated that GZD824 inhibited activation of the GCN2-ATF4 pathway in the ISR.

**Dual Effects of GZD824 on ATF4 Expression.** We next examined the dose-dependent effects of GZD824 on GCN2-ATF4 and PERK-ATF4 pathways. For this purpose, we used histidinol, which mimics amino acid starvation (Zhang et al., 2002), and thapsigargin, a noncompetitive inhibitor of sarco/endo-plasmic reticulum Ca²⁺ ATPase (Urano et al., 2000), as GCN2- and PERK-activating stressors, respectively. Treatments of HT1080 cells with these stressors for 4 hours induced ATF4 as shown by immunofluorescence staining (Fig. 2, A and B). In agreement with the above results, the ATF4 induction by histidinol but not thapsigargin was inhibited by GZD824 in a dose-dependent manner at concentrations ranging from 0.1 to 1 μM. Furthermore, immunoblot analysis revealed that GZD824 dose-dependently suppressed phosphorylation of GCN2 and induction of ATF4 under histidinol stress (Fig. 2C). These results further showed that GZD824 preferentially inhibited activation of the GCN2-ATF4 pathway of the ISR.

During the above examination, we found that GZD824 by itself induced ATF4 expression under normal conditions, peaking at 0.1 μM and attenuating at higher concentrations of 0.3 and 1 μM (Fig. 2, A–C; Supplemental Fig. 2). The ATF4 induction by 0.1 μM GZD824 in HT1080 cells occurred with
a slight increase in phosphorylation of eIF2α S51 but without an increase in phosphorylation of GCN2 T899 (Fig. 2D). In fact, GCN2 phosphorylation was rather decreased by treatment with GZD824. Essentially the same results were obtained using NCI-460 and A549 cells (Fig. 2D). Taken together, GZD824 at low concentrations (~0.1 μM) induced ATF4 expression under normal conditions, but at higher concentrations (0.3–1 μM), it prevented ATF4 induction under GCN2-activating stress conditions.

**GCN2 Kinase as a Direct Molecular Target of GZD824.** Although somewhat paradoxically, impeding GCN2 arm activation by GCN2 knockdown impaired ATF4 induction in HT1080 cells treated with 0.1 μM GZD824 for 4 hours (Fig. 3A). Thus, a low concentration of GZD824 induced ATF4 likely through a GCN2-dependent mechanism. In line with this finding, such a paradoxical effect of GZD824 on ATF4 expression was recapitulated using GCN2iB, a potent ATP-competitive GCN2 kinase inhibitor that has been reported recently (Nakamura et al., 2018). Indeed, similar effects at graded concentrations in the range of 0.001–1 μM, GCN2 kinase activity was assessed by phosphorylation levels of eIF2α S51. In this assay system, GZD824 and GCN2iB similarly inhibited GCN2 kinase activity at 0.1 and 1 μM, but they rather enhanced the activity at 0.001 μM. In contrast, dasatinib did not elicit such dose-dependent effects, although it slightly inhibited GCN2 kinase activity. Docking analysis illustrated that GZD824 was accommodated by the inhibitor-binding pocket of the GCN2 kinase (Fig. 3E). These results suggest that, in a way similar to GCN2iB, GZD824 acts on GCN2 directly and elicits biphasic effects on GCN2 kinase activity depending on the concentration.

**Cellular Sensitization to GCN2-Activating Stress by GZD824.** To examine cellular sensitivity to GZD824, we treated HT1080 cells with this drug (0.5–1 μM) for 48 hours in combination with amino acid deprivation–mimicking stressors histidinol and halofuginone. GZD824 alone slightly inhibited cell growth, but it showed a more potent growth inhibitory activity in the presence of either histidinol or halofuginone (Fig. 4A). The combination of GZD824 and histidinol clearly enhanced apoptosis induction as determined by nuclear fragmentation (Fig. 4B). Similarly, GCN2iB prevented ATF4 induction and reduced cell viability during histidinol
stress, although GCN2iB itself had almost no cytotoxicity (Supplemental Fig. 3). These results suggested that GZD824 sensitized HT1080 cells to amino acid starvation stress, possibly by inhibiting the GCN2 arm of the ISR similarly to GCN2iB.

To examine the effects of combined treatment with GZD824 and histidinol in other cell lines, we used NCI-H460 and A549 cells. In both cell lines, GZD824 effectively prevented phosphorylation of GCN2/eIF2α and induction of ATF4 under 4 hours histidinol stress (Fig. 5A). When both cell lines were treated with GZD824 alone for 48 hours, similar growth inhibition was observed (Fig. 5, B and C). However, sensitization by the combination of GZD824 and histidinol was only seen in NCI-H460 cells but not A549 cells. The precise reason remains unknown, but the lack of the sensitizing effect of GZD824 might be related to the fact that A549 cells exhibited intrinsically higher sensitivity to histidinol than NCI-460 and HT1080 cells.

Taken together, sensitization to amino acid starvation stress by GZD824 was observed in a manner dependent on the cell type.

**Cellular Sensitization to GCN2-Activating Stress by ATF4 Knockdown.** In HT1080 and NCI-460 cells wherein GZD824 elicited stress vulnerability, we examined the effects of ATF4 induction on cellular sensitivity to histidinol. For...
GZD824, which is also known as HQP1351, is an orally available multikinase inhibitor that inhibits imatinib-resistant, mutated BCR-ABL and KIT tyrosine kinases. Based on these activities, GZD824 is currently in clinical trials for chronic myelogenous leukemia and in a preclinical development stage for gastrointestinal stromal tumors (Liu et al., 2019). However, it is unlikely that the inhibitory activity against BCR-ABL and KIT tyrosine kinases may be involved in the GCN2 pathway inhibition of the cancer cells in this study. Rather, our in vitro kinase assay revealed that GZD824 inhibits GCN2 kinase activity as potently as GCN2iB, a recently identified, potent, selective GCN2 inhibitor (Nakamura et al., 2018; Fujimoto et al., 2019). Our results also indicated that GZD824 sensitizes certain cancer cells to amino acid starvation stress, possibly by inhibiting GCN2-elicited ATF4 induction. Thus, GZD824 can be considered as a multikinase inhibitor targeting GCN2.

The GCN2-ATF4 pathway promotes cell survival under nutrient-insufficient settings of the tumor microenvironment and plays a major role in tumor growth (Ye et al., 2010). However, the importance of this pathway for cell survival varies depending on the cell and stress types (Ye et al., 2010; Nakamura et al., 2018), as also observed in this study (Figs. 4 and 5). Therefore, to evaluate the potential of the GCN2-ATF4 pathway as a therapeutic target, GCN2 inhibitors would be useful. In fact, identification of the selective GCN2 inhibitor GCN2iB led to the discovery of a synthetic lethal interaction between GCN2 inhibition and asparagine deprivation in a certain type of cancer cell line (Nakamura et al., 2018). Compared with GCN2iB, GZD824 has a different class of chemical structure and inhibits a different, broad spectrum of kinases in addition to GCN2 (Ren et al., 2013). These distinctive features of GZD824 might be useful to discover novel synthetic lethal interactions and widening the potential of the GCN2-ATF4 pathway as a therapeutic target.

It is likely that GZD824 and GCN2iB both paradoxically activate GCN2 at lower concentrations than those that inhibit the GCN2-ATF4 pathway effectively. In fact, low concentrations of GZD824 induced eIF2α phosphorylation and ATF4 expression in a GCN2-dependent manner in cells under normal nutrient conditions and induced eIF2α phosphorylation in our in vitro GCN2 kinase assay system (Figs. 2 and 3). These were phenocopied by GCN2iB (Fig. 3), which has been reported to inhibit GCN2 most profoundly among 468 kinases examined (Nakamura et al., 2018). Therefore, these observations suggest that the paradoxical activation of GCN2 stems...
from, if not all, the on-target effect of these inhibitors. In this regard, it should be noted that, in contrast to eIF2α phosphorylation and ATF4 induction, T899 autophosphorylation of GCN2 was decreased conversely by low concentrations of GCN2 inhibitors (Figs. 2 and 3). This observation might support the notion that partial inhibition of GCN2 kinase activity occurs during GCN2-eIF2α–ATF4 pathway activation in cells treated with low concentrations of GCN2 inhibitors. So far, GCN2 activation in cell-free systems has been shown to occur by binding of uncharged transfer RNA and, recently, to occur by interactions with ribosomes and the ribosomal P-stalk (Harding et al., 2019). Notably, the latter system indicates that ribosomes stimulate GCN2-dependent eIF2α phosphorylation with no consistent effect on the phosphorylation status of GCN2 T899 (Harding et al., 2019). Thus, it is likely that T899 autophosphorylation of GCN2 is not always a faithful marker for activation of eIF2α-directed kinase activity of GCN2. However, unlike these cell-free systems, neither uncharged transfer RNA nor ribosomes were added in our in vitro system, suggesting that different mechanisms operated in the drug-induced GCN2 activation. Interestingly, a recent study showed that the human GCN2 kinase domain forms a range of conformational states in the presence of ligands bound to the ATP-binding pocket (Maia de Oliveira et al., 2020). Such an unstable nature may raise the possibility that insufficient or partial kinase inhibition by GCN2 inhibitors leads to an active state of eIF2α-directed kinase activity of GCN2. Future studies, especially structural analysis of GCN2 with various GCN2 inhibitors, together with kinetic analysis of the enzymatic activity will be needed to understand the complicated regulation of GCN2 activity.

In summary, we identified GZD824 as a direct GCN2 inhibitor that prevents activation of the GCN2-eIF2α pathway and sensitizes certain cancer cells to amino acid starvation stress. GZD824 will be useful to elucidate the regulatory mechanisms of GCN2 enzymatic activity and evaluate the potential of the GCN2-eIF2α pathway as a target for cancer therapy. Such information may affect current clinical trials and future clinical development of GZD824.

Acknowledgments
We thank Mitchell Arico from Edanz Group (https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript.

Authorship Contributions
Participated in research design: Kato, Tomida.
Conducted experiments: Kato, Takahashi.
Contributed new reagents or analytic tools: Kumimasu, Nagasawa.

References


Address correspondence to: Akihiro Tomida, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. E-mail: akihiro.tomida@jfcr.or.jp